All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

How to Make Clinical Decisions With AI in Oncology

March 27th 2024

Speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.

Clearer Definitions of Added Benefit, Unmet Needs Could Improve EU Oncologic Drug Approval Process

March 27th 2024

Investigators emphasize the importance of firming a widely understood definition of unmet needs in cancer care due to their impact on drug approvals.

FDA Grants Priority Review to Revumenib for R/R KMT2A+ AML/ALL

March 26th 2024

The FDA granted priority review to the NDA seeking the approval of revumenib for the treatment of relapsed/refractory, KMT2A-rearranged acute leukemia.

Navigating First-Line Treatment Options in Advanced, Unresectable HCC

March 26th 2024

Pierre Gholam, MD, discusses primary considerations for the first-line treatment of patients with advanced, unresectable HCC.

Shifting Therapies to Earlier Settings Could Bolster Treatment Options in mHSPC and Oligometastatic Prostate Cancer

March 26th 2024

Neeraj Agarwal, MD, FASCO, discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings.

First-Line Osimertinib Plus Chemo Demonstrates Consistent Benefit in EGFR-Mutant NSCLC

March 26th 2024

Osimertinib plus chemotherapy confers superior post-progression survival outcomes vs osimertinib alone in patients with EGFR-mutated NSCLC.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Retains its Position as New Jersey’s Only National Cancer Institute-Designated Comprehensive Cancer Center

March 26th 2024

Rutgers Cancer Institute of New Jersey along with RWJBarnabas Health was redesignated by the National Cancer Institute.

Japan’s MHLW Approves Zolbetuximab in CLDN18.2-Positive Gastric Cancer

March 26th 2024

The Japanese Ministry of Health, Labour and Welfare has approved zolbetuximab for CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.

SLS009 Generates Positive Topline Data in R/R AML and REGAL Trial Completes Enrollment

March 26th 2024

Positive phase 2a topline findings have been announced with SLS009 plus azacitidine and venetoclax in relapsed/refractory acute myeloid leukemia.

Luspatercept Provides Effective First-Line Alternative to ESAs in Lower-Risk MDS

March 26th 2024

Sunil Iyer, MD, expands on the impact of the FDA’s approval of luspatercept on the management of lower-risk myelodysplastic syndrome.

Handling Parenting Pressures

March 26th 2024

Recent report details the issues early-career oncologists experience regarding parental leave.

A Groundbreaking First in CLL/SLL: Liso-Cel Makes its Mark as Only CAR T-Cell Therapy Approved

March 25th 2024

Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.

First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC

March 25th 2024

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC

March 25th 2024

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

Looking Beyond PSA Is Key to Understanding Nuances of Prostate Cancer Treatment

March 25th 2024

Robert Dreicer, MD, discusses the complex landscape of prostate cancer treatment, highlighting key points from his presentation at the 2024 NY GU.

Liposomal Annamycin Plus Cytarabine Generates Responses in AML

March 25th 2024

Liposomal annamycin plus cytarabine elicited responses in patients with acute myeloid leukemia, according to interim data from the phase 1b/2 MB-106 trial.

Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis

March 25th 2024

Joseph G. Jurcic, MD, highlights findings from the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials in myelofibrosis.

FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma and R/R DLBCL

March 25th 2024

The FDA issued complete response letters to the BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Amer Zeidan, MBBS, MHS, Appointed Inaugural Chief of the Division of Hematologic Malignancies

March 25th 2024

Amer Zeidan, MBBS, MHS, has been appointed inaugural chief of the Division of Hematologic Malignancies at Yale Cancer Center.

Is It Time to Address the Fiscal Reality of the Cancer Care Model and Consider Alternatives?

March 25th 2024

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.